Langdon SP - Search Results

1

NRF2 Regulates HER1 Signaling Pathway to Modulate the Sensitivity of Ovarian Cancer Cells to Lapatinib and Erlotinib.

Kankia IH, Khalil HS, Langdon SP, Moult PR, Bown JL, Deeni YY. Kankia IH, et al. Among authors: langdon sp. Oxid Med Cell Longev. 2017;2017:1864578. doi: 10.1155/2017/1864578. Epub 2017 Dec 19. Oxid Med Cell Longev. 2017. PMID: 29410730 Free PMC article.

2

Sensitivity to pertuzumab (2C4) in ovarian cancer models: cross-talk with estrogen receptor signaling.

Mullen P, Cameron DA, Hasmann M, Smyth JF, Langdon SP. Mullen P, et al. Among authors: langdon sp. Mol Cancer Ther. 2007 Jan;6(1):93-100. doi: 10.1158/1535-7163.MCT-06-0401. Mol Cancer Ther. 2007. PMID: 17237269

3

Hormone therapy for epithelial ovarian cancer.

Langdon SP, Smyth JF. Langdon SP, et al. Curr Opin Oncol. 2008 Sep;20(5):548-53. doi: 10.1097/CCO.0b013e3283063912. Curr Opin Oncol. 2008. PMID: 19106659 Review.

4

Modulation of HER3 is a marker of dynamic cell signaling in ovarian cancer: implications for pertuzumab sensitivity.

Nagumo Y, Faratian D, Mullen P, Harrison DJ, Hasmann M, Langdon SP. Nagumo Y, et al. Among authors: langdon sp. Mol Cancer Res. 2009 Sep;7(9):1563-71. doi: 10.1158/1541-7786.MCR-09-0101. Epub 2009 Sep 8. Mol Cancer Res. 2009. PMID: 19737968

5

Pertuzumab for the treatment of ovarian cancer.

Langdon SP, Faratian D, Nagumo Y, Mullen P, Harrison DJ. Langdon SP, et al. Expert Opin Biol Ther. 2010 Jul;10(7):1113-20. doi: 10.1517/14712598.2010.487062. Expert Opin Biol Ther. 2010. PMID: 20465533 Review.

6

Cancer systems biology.

Faratian D, Bown JL, Smith VA, Langdon SP, Harrison DJ. Faratian D, et al. Among authors: langdon sp. Methods Mol Biol. 2010;662:245-63. doi: 10.1007/978-1-60761-800-3_12. Methods Mol Biol. 2010. PMID: 20824475 Review.

7

Compensatory effects in the PI3K/PTEN/AKT signaling network following receptor tyrosine kinase inhibition.

Goltsov A, Faratian D, Langdon SP, Bown J, Goryanin I, Harrison DJ. Goltsov A, et al. Among authors: langdon sp. Cell Signal. 2011 Feb;23(2):407-16. doi: 10.1016/j.cellsig.2010.10.011. Epub 2010 Oct 14. Cell Signal. 2011. PMID: 20951800 Free article.

8

Features of the reversible sensitivity-resistance transition in PI3K/PTEN/AKT signalling network after HER2 inhibition.

Goltsov A, Faratian D, Langdon SP, Mullen P, Harrison DJ, Bown J. Goltsov A, et al. Among authors: langdon sp. Cell Signal. 2012 Feb;24(2):493-504. doi: 10.1016/j.cellsig.2011.09.030. Epub 2011 Oct 4. Cell Signal. 2012. PMID: 21996585 Free article.

9

Defining the molecular response to trastuzumab, pertuzumab and combination therapy in ovarian cancer.

Sims AH, Zweemer AJ, Nagumo Y, Faratian D, Muir M, Dodds M, Um I, Kay C, Hasmann M, Harrison DJ, Langdon SP. Sims AH, et al. Among authors: langdon sp. Br J Cancer. 2012 May 22;106(11):1779-89. doi: 10.1038/bjc.2012.176. Epub 2012 May 1. Br J Cancer. 2012. PMID: 22549178 Free PMC article.

10

Feedforward and feedback regulation of the MAPK and PI3K oscillatory circuit in breast cancer.

Hu H, Goltsov A, Bown JL, Sims AH, Langdon SP, Harrison DJ, Faratian D. Hu H, et al. Among authors: langdon sp. Cell Signal. 2013 Jan;25(1):26-32. doi: 10.1016/j.cellsig.2012.09.014. Epub 2012 Sep 18. Cell Signal. 2013. PMID: 23000339

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

184 results

Search Page